|Bid||16.15 x 1300|
|Ask||16.89 x 1100|
|Day's Range||15.55 - 18.87|
|52 Week Range||10.37 - 40.91|
|Beta (5Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug 28, 1996|
|1y Target Est||19.00|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
During Friday's "Lightning Round" segment of Mad Money, one caller asked Jim Cramer about the biotech firm CEL-SCI Corp : "I think this one is good," responded Cramer. In this daily bar chart of CVM, below, we can see that prices traded sideways in the $18-$12 area from late April to late January before exploding on the upside. Prices soared sharply to around $40 in a few days and since then prices have been slowly declining back to the breakout level or the top end of the consolidation pattern.
By John Vandermosten, CFA NYSE:CVM First Quarter Fiscal Year 2021 Operational and Financial Results CEL-SCI Corporation (NYSE:CVM) posted a press release and filed its 10-Q for its first quarter of fiscal year 2021 in mid-February. Since our previous report update on January 6, CEL-SCI has continued to monitor its contract research organization’s progress analyzing locked data for the IT-MATTERS